UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million Feb 23, 2026
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease Feb 23, 2026
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States Jan 13, 2026
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission Dec 15, 2025
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology Dec 10, 2025
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights Nov 14, 2025
Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights Nov 12, 2025
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics Nov 06, 2025
Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025 Nov 05, 2025
Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference Oct 24, 2025
